EXECUTIVE SUMMARY
INTRODUCING
ROCKETVAX
Developing next-generation vaccines leveraging its live-attenuated virus technology.
Mission: To develop the next-generation vaccines for established and new indications and address unmet medical need in the treatment and prevention of infectious diseases.
Lead candidates, live attenuated SARS-CoV-2 COVID-19 vaccines RVX-sCPD9 and RVX-OTS: Target underserved market of next-generation COVID-19 vaccine, aiming to manage current and emergent immune-evasive variants and prevent future pandemic through painless needle-free nasal delivery.
20+
Novel variants
in 2024
#1
Excellent Safety
Profile in animal
studies*
3x
Higher efficacy
in animal studies*
$79b
Addressable
Market
* G. Nouailles et al., Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nature Microbiology, 2023, DOI: 10.1038/s41564-023-01352-8. J. Trimpert et al,. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Reports, 2021, DOI:10.1016/j.celrep.2021.109493
THE CHANGING
GLOBAL THREAT
OF COVID-19
2024 FIGURES1
44K
COVID-19 Deaths
in the US
7.7
Peak
hospitalization
(per 100,000)1
Majority of COVID-19 cases
every year
are caused by new
variants1
In 2024, COVID-19 remained a public health threat as the virus continued to mutate causing periodic surges, with majority of new diagnoses caused by novel variants that cannot be effectively mitigated by currently available vaccines.
Although the impact of COVID-19 is no longer as visible as during the peak lockdown period, there is no doubt COVID-19 is here to stay.
CURRENTLY AVAILABLE VACCINE OPTIONS
ALL FALL SHORT
DECLINING
EFFICACY
Efficacy wanes over time, with an estimated 2x drop in effective protection from infection and death after 22 weeks.
Figures adapted from: pmc.ncbi.nlm.nih.gov/articles/PMC11197991
DELIVERY
LIMITATIONS
Currently approved vaccines are mainly injectable, which is inconvenient. In addition, specific storage requirements result in several supply chain limitations.
Rocketvax AG develops next-generation live-attenuated virus vaccines, including a novel nasal vaccine candidate for SARS-CoV-2.
The lead candidates RVX-sCPD9 and RVX-OTS have demonstrated excellent results in animal studies, showcasing tremendous promise to offer superior patient outcomes for both existing and emerging SARS-CoV-2 variants.
LONG-TERM
IMMUNITY
DIFFERENTIATED
TECHNOLOGY
EFFECTIVE
BOOSTER
HIGHLY
SCALABLE
NEEDLE-FREE
DELIVERY
BROAD
EFFICACY
ESTABLISHED
SUPPLY CHAIN
EXCELLENT
TOLERABILITY
STABLE
FORMULATION
All data
is preclinical
Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by
genome recoding. Cell Reports, 2021, DOI: 10.1016/j.celrep.2021.109493
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2
variants in hamsters. Nature Microbiology, 2023, DOI: 10.1038/s41564-023-01352-8
A non-transmissible live attenuated SARS-CoV-2 vaccine. Molecular Therapy, 2023, DOI:
10.1016/j.ymthe.2023.05.004
An Intranasal Live-attenuated SARS-CoV-2 Vaccine Limits Virus Transmission. Nature
Communications, 2024, DOI: 10.1038/s41467-024-45348-2
Schon, J., Barut, G. T. et al. A safe, effective and adaptable live-attenuated SARS-CoV-2
vaccine to reduce disease and transmission using one-to-stop genome modifications.
Nature Microbiology, July 2024, DOI: https://doi.org/10.1038/s41564-024-01755-1
All data is preclinical
Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by
genome recoding. Cell Reports, 2021, DOI: 10.1016/j.celrep.2021.109493
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2
variants in hamsters. Nature Microbiology, 2023, DOI: 10.1038/s41564-023-01352-8
A non-transmissible live attenuated SARS-CoV-2 vaccine. Molecular Therapy, 2023, DOI:
10.1016/j.ymthe.2023.05.004
An Intranasal Live-attenuated SARS-CoV-2 Vaccine Limits Virus Transmission. Nature
Communications, 2024, DOI: 10.1038/s41467-024-45348-2
Schon, J., Barut, G. T. et al. A safe, effective and adaptable live-attenuated SARS-CoV-2
vaccine to reduce disease and transmission using one-to-stop genome modifications.
Nature Microbiology, July 2024, DOI: https://doi.org/10.1038/s41564-024-01755-1
REVOLUTIONARY BENEFITS
OF INTRANASAL DELIVERY
CAVITY
Long-term multifaceted immunity against current and future SARS-CoV-2 variants1
Local immunity at the site of virus entry (upper respiratory tissues)2
Reduction of both virus infection and transmission3
Potential to curb any future COVID-19 pandemic
Ease of administration
All Preclinical Data:
1. G. Nouailles et al., Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic
immunity to SARS-CoV-2 variants in hamsters. Nature Microbiology, 2023, DOI:
10.1038/s41564-023-01352-8
2. J. Trimpert et al,. Development of safe and highly protective live-attenuated SARS-CoV-2
vaccine candidates by genome recoding. Cell Reports, 2021, DOI:
10.1016/j.celrep.2021.109493).
3. Adler JM, et al. (2023). Schon, J., Barut, G. T. et al. A safe, effective and adaptable
live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome
modifications. Nature Microbiology, July 2024, DOI: https://doi.org/10.1038/s41564-024-01755-1
SUPERIOR INNOVATION AND PRODUCT-MARKET FIT
EVIDENCED BY
US GOVERNMENT BACKING
SUPERIOR INNOVATION AND PRODUCT-MARKET FIT
EVIDENCED BY US GOVERNMENT BACKING
Under the US government Project NextGen, Rocketvax AG has signed a letter of intent with the Division of Microbiology and Infectious Diseases (DMID) and the National Institute of Allergy and Infectious Diseases (NIAID) outlining the intended collaboration between the parties for conduct* and sponsoring of a clinical trial investigating Rocketvax AG's RVX-sCPD9 candidate.
Project NextGen is a $5bn public initiative aimed at accelerating and streamlining the rapid development of the next generation of vaccines and treatments through public-private collaborations.
*Clinical Trial Agreement to be signed prior to commencement of clinical trial to develop sCPD9 vaccine, nasal COVID-19 vaccine of Rocketvax AG.
LATEST NEWS
Download Our
Company Presentation
your name
your email
organization name